arrow_back Back to Home
InGoodHands
Talk to Expert
prescriptions
Instant Prescription Path · India

Qualified for GLP-1 Therapy in India?

Speak to an InGoodHands Doctor today for blood panel evaluation and prescription fulfillment across all major Indian cities.

Assess Eligibility arrow_downward
verified_user Medically reviewed by Dr. Brij Teli | Medical Director, InGoodHands India · Updated July 2026

GLP-1 & Ozempic Eligibility Calculator (South Asian ESI 2025 Adjusted)

Calculate your personalized weight loss timeline and clinical eligibility for Semaglutide (Ozempic, Wegovy) or Tirzepatide (Mounjaro) in India using ESI 2025 and FDA guidelines.

tune 1. Personalize Your Physical & Clinical Profile

Provide your measurements to calculate your BMI under South Asian or FDA criteria.

India ESI 2025 Standard
verified
Clinical Eligibility Guidelines Clinical qualification begins at BMI ≥ 30 (or BMI 27–30 with metabolic comorbidities like PCOS, Prediabetes, Hypertension, or Fatty Liver).
Height Input Mode
monitor_weight kg
Range: 35 - 300 kg
adjust kg
Must be less than current weight
height cm
Used to calculate starting BMI
cake yrs
Must be 18 or older to enroll
health_and_safety

Absolute Safety Screening (Hard Stops)

Strict clinical contraindications mandated by FDA & Indian Medical Council guidelines.

Required Check

Please select any of the following safety conditions that apply to you. Prescribing is strictly restricted if any hard stop criteria are present:

Results Projection
Expected Loss (48 Wks) —
Timeline to Target
—
Recommended Daily Targets (Muscle Preservation)
Calories —
Protein —
Carbs —
Fats —
💡 High protein intake is essential to defend lean muscle mass during GLP-1 weight reduction.
Calculated Starting BMI: — Loading...
Target Weight Feasibility

Weight Projection Timeline Weeks 0 to 48
chat
Get Full Report on WhatsApp Send your clinical eligibility score & titration roadmap directly to WhatsApp.
send Send Report to WhatsApp

assignment Your Personalized Weight Loss Plan

Based on your goals, you'll need approximately — weeks to lose — kg and reach your target weight of — kg using —.

📋 Your Success Checklist
✅
Moderate Calorie Deficit Reduce daily intake by 500-750 calories
✅
Daily Protein Target Consume —g of protein daily
✅
Resistance Training Complete 2-3 strength workouts per week
✅
Daily Hydration Drink — liters of water daily

medical_services 2. Medical Consultation & Lead Intake

Submit your details for doctor review or to schedule your medical consultation in India.

person
+91
phone
InGoodHands Clinical Protocol Summary
medical_information Obesity Expert Voice Call Consultation: Comprehensive review of clinical history and metabolic baseline (₹49 consult fee).
lab_research Diagnostic Blood Panel: Analysis of thyroid (TSH), blood sugar (HbA1c), liver, and kidney health markers to confirm candidacy.
monitoring Precision Dose Titration: Gradual titration schedules monitored weekly to manage side effects and adapt to lowest effective doses.
Update your inputs to verify clinical eligibility criteria.

🔒 Your health history is fully private and evaluated strictly under medical supervision guidelines.

shield_with_heart
Medical & Clinical Disclaimer (India)

This eligibility assessment is a statistical screening tool based on Endocrine Society of India (ESI 2025) and FDA criteria for informational purposes only. It does not constitute medical advice, diagnosis, or a prescription.

GLP-1 receptor agonists (Semaglutide, Tirzepatide) are prescription-only medications in India. Treatment authorization requires direct physician consultation, comprehensive baseline blood work (HbA1c, LFT, KFT, Thyroid), and continuous clinical supervision by an endocrinologist.

The Clinical Evidence & Guidelines Behind Our Calculator

To maintain strict medical accuracy for Indian patients under YMYL health standards, our computational models incorporate peer-reviewed clinical trial data alongside ethnicity-adjusted guidance from the Endocrine Society of India (ESI 2025).

Clinical Eligibility Standards

Under standard clinical prescribing criteria, qualification begins at BMI ≥ 30 for obesity, or BMI 27–30 when accompanied by at least one metabolic comorbidity (such as Prediabetes, Hypertension, or Dyslipidemia).

The STEP-1 Trial — Semaglutide Efficacy

Published in NEJM, the STEP-1 trial evaluated once-weekly Semaglutide over 68 weeks, achieving an average total body weight loss of 14.9% Wilding et al., 2021, PMID: 33567185 open_in_new.

The SURMOUNT-1 Trial — Tirzepatide Efficacy

Evaluating dual GIP/GLP-1 receptor agonist Tirzepatide (Mounjaro), participants escalating to 15 mg weekly achieved an average weight reduction of 22.5% over 72 weeks Jastreboff et al., 2022, PMID: 35658024 open_in_new.

GLP-1 Clinical Benchmarks in India
Medication Pathway Form Factor in India Average Weight Loss % Standard Titration Schedule
Semaglutide (Ozempic/Wegovy) Once-Weekly Subcutaneous Injectable ~14.9% of body weight 0.25mg → 0.5mg → 1.0mg → 1.7mg → 2.4mg
Tirzepatide (Mounjaro) Once-Weekly Subcutaneous Injectable ~22.5% of body weight 2.5mg → 5.0mg → 7.5mg → 10mg → 12.5mg → 15mg
FAQ & Clinical Guidance

Frequently Asked Questions About GLP-1 & Ozempic in India

Under standard clinical prescribing guidelines, individuals with a BMI ≥ 30 are clinically eligible for doctor-supervised obesity care. Individuals with a BMI between 27 and 30 are eligible when accompanied by at least one weight-related metabolic comorbidity, such as Prediabetes, Type 2 Diabetes, Hypertension, Dyslipidemia, or PCOS.
Semaglutide (Ozempic, Wegovy) acts purely on GLP-1 receptors to slow gastric emptying and suppress appetite. Tirzepatide (Mounjaro) is a dual GIP and GLP-1 receptor agonist, targeting two metabolic pathways simultaneously. In clinical trials, Tirzepatide demonstrated higher average weight reduction (~22.5%) compared to Semaglutide (~14.9%).
Escalating doses too quickly can cause gastrointestinal discomfort such as nausea, reflux, or changes in bowel habits. Starting at lower doses (e.g. 0.25mg Semaglutide or 2.5mg Tirzepatide) allows your digestive system to adapt comfortably while maintaining sustained appetite suppression.
Qualifying comorbidities include Prediabetes, Type-2 Diabetes, PCOS, Hypertension, Dyslipidemia (high cholesterol), Non-Alcoholic Fatty Liver Disease (NAFLD), and Obstructive Sleep Apnea.
Contraindications include a personal or family history of Medullary Thyroid Carcinoma (MTC), Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), active pancreatitis, pregnancy, breastfeeding, or severe end-stage renal disease.
Yes. Baseline diagnostic blood panels evaluating HbA1c, TSH, liver function (LFT), and renal function (KFT) are required by our endocrinologists before issuing any GLP-1 prescription.
Yes. GLP-1 medications significantly improve insulin sensitivity, reduce visceral adiposity, and lower hepatic fat accumulation, making them highly beneficial for individuals managing PCOS and fatty liver disease under medical supervision.
After completing the checker, you can schedule a 1-on-1 virtual consultation with a certified endocrinologist who reviews your clinical intake, arranges lab tests, and crafts your custom titration protocol.
Yes. All prescriptions are written by licensed medical doctors in full compliance with CDSCO and Telemedicine Practice Guidelines, with direct doorstep medication delivery across major cities in India.
If our specialist doctor determines during medical review that GLP-1 therapy is unsuitable or unsafe for your specific profile, any consultation fees paid are 100% refunded immediately.